Caricamento...
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and has a median survival after diagnosis of 2–5 years. Pirfenidone is the first approved antifibrotic drug for the treatment of IPF. Here we report the functional progress, side effects and survival...
Salvato in:
| Pubblicato in: | Ther Adv Respir Dis |
|---|---|
| Autori principali: | , , , , , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7029533/ https://ncbi.nlm.nih.gov/pubmed/32066332 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466620906326 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|